SCHEMBL2964396

SCHEMBL2964396

CC(=O)c1ccc(Oc2ccc(Cl)cc2N)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.66
SMN1; SMN2 Q16637 4/20 0.66
HPGD P15428 3/20 0.66
KMT2A Q03164 3/20 0.66
CYP1A2 P05177 2/20 0.66
CYP2C9 P11712 2/20 0.66
CYP2C19 P33261 2/20 0.66
KDM4E B2RXH2 2/20 0.66
ALDH1A1 P00352 2/20 0.66
MEN1 O00255 1/20 0.66
CYP2D6 P10635 1/20 0.66
CYP3A4 P08684 1/20 0.59
HTT P42858 2/20 0.54
LMNA P02545 2/20 0.54
RAB9A P51151 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.52
USP2 O75604 1/20 0.48
CREBBP Q92793 1/20 0.48
MAOA P21397 2/20 0.47
MAOB P27338 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1283828 0.84 FFAR1 (0.57) MAPTHPGDLMNARAB9AMAOA
SCHEMBL2963639 0.84 MAPT (0.60) MAPTSMN1; SMN2HPGDKMT2ACYP1A2
SCHEMBL2970972 0.82 MAPT (0.62) MAPTSMN1; SMN2HPGDKMT2ACYP1A2
SCHEMBL2970975 0.82 MAPT (0.62) MAPTSMN1; SMN2HPGDKMT2ACYP1A2
SCHEMBL756150 0.82 MAPT (0.53) MAPTSMN1; SMN2HPGDLMNARAB9A
SCHEMBL9657030 0.82 MAPT (0.49) MAPTSMN1; SMN2HPGDKMT2ACYP1A2
SCHEMBL32674568 0.82 MAPT (0.96) MAPTSMN1; SMN2HPGDKMT2ACYP1A2
SCHEMBL7140487 0.82 MAPT (0.96) MAPTSMN1; SMN2HPGDKMT2ACYP1A2
SCHEMBL2966329 0.81 KMT2A (0.60) MAPTSMN1; SMN2HPGDKMT2ACYP1A2
SCHEMBL2961914 0.81 ALDH1A1 (0.56) MAPTSMN1; SMN2HPGDKMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338605-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2012-12-25 US disclosed
US-20100256139-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2010-10-07 US disclosed
EP-1979349-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2010-07-28 EP disclosed
US-7763731-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2010-07-27 US disclosed
US-20070232645-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232645-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 MAPT 1347/4885SMN1; SMN2 3135/4885HPGD 3704/4885
US-20100256139-A1 Anti-Viral Compounds HAVCR2, MAVS, EIF2AK2 MAPT 1347/4885SMN1; SMN2 3135/4885HPGD 3704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.